Strides Pharma (STAR.NS)

Executive Summary

Strides Pharma is a leading global pharmaceutical manufacturer headquartered in Bengaluru, India, specializing in complex generics, biosimilars, and specialty formulations. With a presence in over 100 countries and multiple USFDA-approved facilities, the company leverages advanced formulation expertise in softgels, injectables, and controlled substances. Its hybrid business model, spanning branded and plain generics, positions it as a trusted supplier to healthcare systems worldwide. Listed on the NSE (ticker: STAR.NS) with a market valuation of approximately $86.43 billion, Strides combines manufacturing excellence with affordability, serving both regulated and emerging markets. The company's strategic focus on high-barrier-to-entry products and its robust pipeline in complex generics and biosimilars underpin its growth trajectory. Recent completion of a Phase 2 trial for Favipiravir + Nitazoxanide in COVID-19 highlights R&D capabilities, though near-term catalysts are likely tied to USFDA approvals for complex generics and biosimilar launches. With a strong foothold in controlled substances and injectables, Strides is well-positioned to capitalize on upcoming patent expirations and supply chain diversification trends. The company's financial stability and operational scale provide a solid foundation for sustained value creation.

Upcoming Catalysts (preview)

• Q4 2026USFDA approval for a complex generic (e.g., a first-to-file softgel or injectable)70% success
• 2027Launch of a biosimilar product in a regulated market (US or EU)60% success
• H2 2026Strategic partnership or acquisition to expand controlled substance manufacturing capacity50% success